triazoles has been researched along with ly 518674 in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barr, RJ; Bean, JS; Bensch, WR; Dominianni, SJ; Huang, N; Kauffman, RF; Luffer-Atlas, D; Maise, DE; Mantlo, NB; Mayhugh, D; Montrose-Rafizadeh, C; Osborne, J; Rungta, D; Saeed, A; Singh, J; Thompson, RC; Wang, X; Xu, Y; Yumibe, NP; Zink, RW | 1 |
| Bean, J; Bensch, W; Kauffman, R; Mantlo, N; McClelland, P; Montrose, C; Singh, JP; Wagle, A; Wang, G | 1 |
| Gomez, EV; Howey, DC; McErlean, E; Nicholls, SJ; Nissen, SE; Russo, JM; Wang, MD; Wolski, K | 1 |
| Gonzalez, FJ; Hossain, MA; Tsujita, M; Yokoyama, S | 1 |
| Bloedon, LT; Duffy, D; Dunbar, RL; Fuki, IV; Gadi, R; Harris, CJ; Howey, DC; McCoy, M; Millar, JS; Movva, R; Rader, DJ; Shah, A; Wang, MD; Wolfe, ML | 1 |
| Akita, N; Fukutomi, T; Gonzalez, FJ; Hossain, MA; Kimura, G; Ogata, M; Staels, B; Suzuki, S; Tsujita, M; Yokoyama, S | 1 |
| Kim, JB; Mahdavi, H; Navab, M; Safarpour, S; Tien, DA | 1 |
| Millar, JS; Rader, DJ; Shah, A | 1 |
| Baccei, CS; Bravo, Y; Broadhead, A; Bundey, R; Chen, A; Clark, R; Correa, L; Jacintho, JD; Lorrain, DS; Messmer, D; Prasit, P; Stebbins, K; Stock, N | 1 |
| Khera, AV; Millar, JS; Rader, DJ; Ruotolo, G; Wang, MD | 1 |
1 review(s) available for triazoles and ly 518674
| Article | Year |
|---|---|
The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans.
Topics: Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Humans; PPAR alpha; Propionates; Triazoles | 2010 |
3 trial(s) available for triazoles and ly 518674
| Article | Year |
|---|---|
Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
Topics: Atorvastatin; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; PPAR alpha; Propionates; Pyrroles; Triazoles | 2007 |
Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, VLDL; Deuterium; Double-Blind Method; Female; Humans; Kinetics; Male; Metabolic Syndrome; Middle Aged; Placebos; PPAR alpha; Propionates; Triazoles; Triglycerides; Young Adult | 2009 |
Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome.
Topics: Apolipoprotein A-I; Apolipoproteins B; Cholesterol, HDL; Female; Humans; Male; Metabolic Syndrome; Middle Aged; PPAR alpha; Propionates; Triazoles | 2015 |
6 other study(ies) available for triazoles and ly 518674
| Article | Year |
|---|---|
Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist.
Topics: Administration, Oral; Animals; Apolipoprotein A-I; Binding, Competitive; Biological Availability; Cell Line; Dogs; Drug Design; Humans; Mice; Mice, Transgenic; Propionates; Radioligand Assay; Rats; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship; Transcription Factors; Transfection; Triazoles | 2003 |
Identification of a novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy)propanoic acid (LY518674), that produces marked changes in serum lipi
Topics: Animals; Apolipoprotein A-I; Base Sequence; Cells, Cultured; Cholesterol, HDL; DNA Primers; Humans; In Vitro Techniques; Liver; Macaca fascicularis; Mice; Mice, Transgenic; PPAR alpha; Propionates; RNA, Messenger; Triazoles | 2005 |
Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Bezafibrate; Blotting, Western; Cells, Cultured; Fenofibrate; Gemfibrozil; Gene Expression Regulation; Hepatocytes; Hypolipidemic Agents; Lipoproteins, HDL; Mice; Mice, Inbred C57BL; Mice, Knockout; Peroxisome Proliferator-Activated Receptors; Propionates; Triazoles | 2008 |
On the mechanism for PPAR agonists to enhance ABCA1 gene expression.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Bezafibrate; Cell Line, Tumor; Fenofibrate; Fibroblasts; Gemfibrozil; Gene Expression Regulation; Humans; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pioglitazone; PPAR delta; PPAR gamma; Propionates; Thiazoles; Thiazolidinediones; Triazoles | 2009 |
Dyslipidemia and cardiovascular diseases.
Topics: Benzimidazoles; Cardiovascular Diseases; Dyslipidemias; Humans; Lipoproteins, HDL; Niacin; Propionates; Triazoles | 2009 |
Identification of the first potent, selective and bioavailable PPARα antagonist.
Topics: Animals; Butyrates; Humans; Mice; Molecular Structure; Oxazoles; Phenylurea Compounds; PPAR alpha; Propionates; Structure-Activity Relationship; Sulfonamides; Triazoles; Tyrosine | 2014 |